Orchestra BioMed Holdings (OBIO) Amortizatization of Intangibles (2022 - 2026)
Orchestra BioMed Holdings (OBIO) posted quarterly Amortizatization of Intangibles of $77000.0 for Q1 2026, down 31.25% year-over-year from $112000.0 in Q1 2025, and down 75.94% quarter-over-quarter from $320000.0 in Q4 2025.
Powered by 
Analysis
Orchestra BioMed Holdings (OBIO) Amortizatization of Intangibles (2022 - 2026) Analysis & Trends
Orchestra BioMed Holdings (OBIO) has reported Amortizatization of Intangibles for 4 consecutive years, with $77000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Amortizatization of Intangibles fell 31.25% year-over-year to $77000.0; the TTM figure through Mar 2026 stood at $776000.0 (down 24.22% YoY), while the FY2025 annual figure was $811000.0, down 45.97% from the prior year.
- Amortizatization of Intangibles fell to $77000.0 in Q1 2026 per OBIO's latest filing, from $320000.0 in the prior quarter.
- Across five years, Amortizatization of Intangibles topped out at $1.1 million in Q3 2023 and bottomed at $49000.0 in Q2 2025.
- Historically, Amortizatization of Intangibles has averaged $477538.5 across 4 years, with a median of $330000.0 in 2025.
- On a YoY basis, Amortizatization of Intangibles climbed as much as 38.53% in 2025 and fell as far as 84.92% in 2025.
- Orchestra BioMed Holdings' Amortizatization of Intangibles stood at $638000.0 in 2023, then plunged by 63.79% to $231000.0 in 2024, then jumped by 38.53% to $320000.0 in 2025, then plunged by 75.94% to $77000.0 in 2026.
- Business Quant data shows OBIO's Amortizatization of Intangibles at $77000.0 in Q1 2026, $320000.0 in Q4 2025, and $330000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 4.33 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 678,000.00 |
| 10 | Orchestra BioMed Holdings | 322.25 Mn | 127.72 Mn | 63,000.00 | 317,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 317,000.00 |
| Mar 31, 2026 | 159,000.00 |
| Dec 31, 2025 | 320,000.00 |
| Sep 30, 2025 | 194,000.00 |
| Jun 30, 2025 | 150,000.00 |
| Mar 31, 2025 | 147,000.00 |
| Dec 31, 2024 | 231,000.00 |
| Sep 30, 2024 | 356,000.00 |
| Jun 30, 2024 | 325,000.00 |
| Mar 31, 2024 | 589,000.00 |
| Dec 31, 2023 | 638,000.00 |
| Sep 30, 2023 | 1.06 Mn |
| Jun 30, 2023 | 1.06 Mn |
| Mar 31, 2023 | 1.06 Mn |
| Dec 31, 2022 | 181,000.00 |
| Sep 30, 2022 | 150,000.00 |
| Jun 30, 2022 | 137,000.00 |
| Mar 31, 2022 | 132,000.00 |